A LONG-LASTING SOLUTION FOR DRY EYE DISEASE USING PATENTED IRPL® TECHNOLOGY
(Intense Regulated Pulsed Light)
E>Eye is the first medical device in the world using IRPL® technology that has been specifically designed for the treatment of dry eyes due to meibomian gland dysfunction (MGD).
Meibomian gland dysfunction has been identified as a principal cause of dry eye disease. It results in the tear film becoming unstable, leading to insufficient production, or excessive evaporation of tears. It is now acknowledged that most cases of evaporative dry eye are primarily due to a compromised external lipid layer of the lacrimal film, caused by malfunctioning meibomian glands.
How IRPL® Technology Works
E>Eye is a dry eye treatment that generates a new polychromatic pulsed light by producing perfectly calibrated and homogeneously sequenced light pulses. The sculpted pulses are delivered under the shape of regulated train pulses. The energy, spectrum and time period are precisely set to stimulate the meibomian glands to improve their function.
Easy to Use, Fast, and Tailor-Made for Optometrists & Ophthalmologists
- E>Eye is user-friendly and intuitive with no risk for errors.
- A treatment session can begin within a few seconds and takes only three minutes to perform.
- No preheating is required
- The E>Eye is a compact device that will fit into any eye care professional’s practice space.
Simple & Fast
Session treatments take only a few minutes.
- Patients are comfortably seated on a treatment chair, preferably tilted. The metal eyewear protection is adjusted on the patient’s eyes. Optical gel is then applied to the cheekbone and the temporal areas.
- A series of 5 flashes is applied under one eye, starting from the inner canthus up to the temporal area, using the nominal power.
- The same process is then repeated under the other eye.
IRPL® treatments lead to an improvement in the function of the meibomian glands in a very short amount of time (approximately two hours) following the treatment.
The full success of treatment depends on compliance with a specific protocol. For optimal results, perform treatments on Day One, Day 15, and Day 45, and then as needed according to the patient’s symptoms.
Clinical studies have been conducted in France, New Zealand, and China. These studies have shown the following:
- A considerable improvement in the symptoms perceived by patients, with a 90% satisfaction rate after the first two treatments.
This improvement was confirmed by patients’ opinions regarding their level of discomfort before treatment versus their level of discomfort after treatment, as well as the improvement in fixation time while reading or watching television. An improvement was felt by patients quickly following the initial treatment, and for several days after treatment. Perceived improvements became more prolonged after the second and third treatments.
- A correlation between patients’ perceptions and clinical measurements executed.
45% of patients originally classified as level 2 (Oxford classification) have, after the instillation of fluorescein, improved by one or two levels. 81% of patients from level 1 have improved by one level.
These results were obtained two months (on average) after the third treatment.
Patients suffering from a more severe pathology, classified on the 3rd and 4th levels, will need to treat both inferior and superior eyelids. The ocular globe would need to be protected by a haptic contact lens. In these cases, improvement by one to two levels is expected.
This clinical trial conducted by Dr. Shaun MacInnis shows the benefits of E>Eye with IRPL® technology for MGD management. The addition of E>Eye to MGD standard of care resulted in significant patient improvement at day 105 of the trial, measured through NITBUT, MG Score, and OSDI, showing the effectiveness of E>Eye at stimulating the increase in both quality and quantity of meibum. View full study.
View the advantages of exclusive IRPL® technology versus conventional IPLs below.
IRPL® vs IPL COMPARISON TABLE
1 Dr. Christian MALBREL, Ophthalmologist, 2013, Treatment with a polychromatic pulsed light device for a dysfunction described as “dry eye” in the form of a corneal condition associated with a deficiency in the lipid layer
A manufacturer and a product you can trust:
- Received Medical CE Certification approval (European Standard) & TGA registration approval in 2013
- Comes with a 2-Year Warranty
- New, Safe and Effective IRPL® Technology (Intense Regulated Pulsed Light)
- Made in France by E-Swin, the world’s largest medical IPL manufacturer.
- Certified ISO 9001 and ISO 13485